ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS
ROBERTS PHARMACEUTICAL ANNOUNCES ACQUISITION OF CURRENTLY MARKETED
ANTI-PARKINSON DRUG FROM NORWICH EATON PHARMACEUTICALS
EATONTOWN, N.J., Dec. 10 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has purchased exclusive rights to Dopar(R), an anti-Parkinson prescription pharmaceutical product currently sold by Norwich Eaton Pharmaceuticals, Inc. of Norwich, N.Y.
Norwich Eaton is a wholly owned subsidiary of The Procter & Gamble Company (NYSE: PG). Roberts will immediately begin active marketing for Dopar through its own sales and marketing organization. Financial terms were not disclosed.
Dopar is prescribed predominantly by specialists for the symptomatic treatment of Parkinson's Disease. Roberts chairman and CEO, Dr. Robert Vukovich, commented on the purchase, "The acquisition of Dopar forms the basis for the early establishment of a relationship between Roberts and neurologic specialists. This relationship will be of significant advantage to our company when we receive FDA approval for Amatine, another product to be promoted to neurologists."
Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
/CONTACT: Anthony P. Maris of Roberts Pharmaceutical, 908-389-1182/
(RPCX PG) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: TNM FC-TS -- NY019 -- 0929 12/10/91 10:25 EST